Babcock & Wilcox (B&W) Technical Services Group has named Daniel Glenn as head of research and development for the Lynchburg, VA, company's medical isotope program.
Glenn most recently served as technical deputy manager for the U.S. Department of Energy's Los Alamos National Laboratory.
B&W in January announced a collaboration with radiopharmaceutical firm Covidien of Hamilton, Bermuda, to develop new nuclear reactor technology that's less complex, less expensive, and more environmentally friendly than traditional reactors used for the production of molybdenum-99, the precursor to technetium-99m.
Related Reading
Covidien, B&W to tackle medical isotope dilemma, January 28, 2009
Report: Use of low-enriched uranium in medical isotopes is feasible, January 15, 2009
SNM draft report shows U.S. Mo-99 production years away, July 22, 2008
Copyright © 2009 AuntMinnie.com